Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND PTEN, MMAC1, 5728, MGC11227, PTEN1, MHAM, P60484, BZS, ENSG00000171862 AND Clinical Outcome
22 results:

  • 1. Genomic Landscape of Primary Tumor Site and clinical outcome for Patients with Metastatic colorectal cancer Receiving Standard-of-Care Chemotherapy.
    Mizukami T; Takahashi M; Sunakawa Y; Yuki S; Kagawa Y; Takashima A; Kato K; Hara H; Denda T; Yamamoto Y; Shiozawa M; Oki E; Okamoto W; Yoshino T; Eguchi Nakajima T
    Target Oncol; 2022 May; 17(3):343-353. PubMed ID: 35524872
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Combined Analysis of EGFR and pten Status in Patients With KRAS Wild-Type Metastatic colorectal cancer.
    Chen Y; Shi Y; Lin J; Ye YB; Wang XJ; Chen G; Guo ZQ
    Medicine (Baltimore); 2015 Oct; 94(40):e1698. PubMed ID: 26448020
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.
    Oberst MD; Fuhrmann S; Mulgrew K; Amann M; Cheng L; Lutterbuese P; Richman L; Coats S; Baeuerle PA; Hammond SA
    MAbs; 2014; 6(6):1571-84. PubMed ID: 25484061
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial.
    Thomaidis T; Maderer A; Formentini A; Bauer S; Trautmann M; Schwarz M; Neumann W; Kittner JM; Schad A; Link KH; Rey JW; Weinmann A; Hoffman A; Galle PR; Kornmann M; Moehler M
    J Exp Clin Cancer Res; 2014 Oct; 33(1):83. PubMed ID: 25272957
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer.
    Valeri N; Braconi C; Gasparini P; Murgia C; Lampis A; Paulus-Hock V; Hart JR; Ueno L; Grivennikov SI; Lovat F; Paone A; Cascione L; Sumani KM; Veronese A; Fabbri M; Carasi S; Alder H; Lanza G; Gafa' R; Moyer MP; Ridgway RA; Cordero J; Nuovo GJ; Frankel WL; Rugge M; Fassan M; Groden J; Vogt PK; Karin M; Sansom OJ; Croce CM
    Cancer Cell; 2014 Apr; 25(4):469-83. PubMed ID: 24735923
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Is biomarker research advancing in the era of personalized medicine for head and neck cancer?
    Yokota T
    Int J Clin Oncol; 2014 Apr; 19(2):211-9. PubMed ID: 24442754
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Altered pten function caused by deletion or gene disruption is associated with poor prognosis in rectal but not in colon cancer.
    Bohn BA; Mina S; Krohn A; Simon R; Kluth M; Harasimowicz S; Quaas A; Bockhorn M; Izbicki JR; Sauter G; Marx A; Stahl PR
    Hum Pathol; 2013 Aug; 44(8):1524-33. PubMed ID: 23465274
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/pten, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of pten is associated with worse clinical outcome.
    Bettstetter M; Berezowska S; Keller G; Walch A; Feuchtinger A; Slotta-Huspenina J; Feith M; Drecoll E; Höfler H; Langer R
    Hum Pathol; 2013 May; 44(5):829-36. PubMed ID: 23158210
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.
    Kim SY; Shim EK; Yeo HY; Baek JY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Jung KH; Chang HJ
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):201-7. PubMed ID: 22672749
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.
    Custodio A; Feliu J
    Crit Rev Oncol Hematol; 2013 Jan; 85(1):45-81. PubMed ID: 22647972
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Loss of pten expression as a predictor of resistance to anti-EGFR monoclonal therapy in metastatic colorectal cancer: evidence from retrospective studies.
    Wang ZH; Gao QY; Fang JY
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1647-55. PubMed ID: 22610356
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study.
    Ulivi P; Capelli L; Valgiusti M; Zoli W; Scarpi E; Chiadini E; Rosetti P; Bravaccini S; Calistri D; Saragoni L; Casadei Gardini A; Ragazzini A; Frassineti GL; Amadori D; Passardi A
    J Transl Med; 2012 May; 10():87. PubMed ID: 22569004
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Rescue of glandular dysmorphogenesis in pten-deficient colorectal cancer epithelium by PPARγ-targeted therapy.
    Jagan I; Fatehullah A; Deevi RK; Bingham V; Campbell FC
    Oncogene; 2013 Mar; 32(10):1305-15. PubMed ID: 22543585
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. [Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].
    Fabian P; Berkovcová J
    Cesk Patol; 2011 Oct; 47(4):154-8. PubMed ID: 22145213
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?
    Inno A; Di Salvatore M; Cenci T; Martini M; Orlandi A; Strippoli A; Ferrara AM; Bagalà C; Cassano A; Larocca LM; Barone C
    Clin Colorectal Cancer; 2011 Dec; 10(4):325-32. PubMed ID: 21729677
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Colonic polyposis and neoplasia in Cowden syndrome.
    Stanich PP; Owens VL; Sweetser S; Khambatta S; Smyrk TC; Richardson RL; Goetz MP; Patnaik MM
    Mayo Clin Proc; 2011 Jun; 86(6):489-92. PubMed ID: 21628613
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer.
    Spindler KL; Pallisgaard N; Lindebjerg J; Frifeldt SK; Jakobsen A
    BMC Cancer; 2011 Mar; 11():107. PubMed ID: 21439039
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. clinical significance of tumor suppressor pten in colorectal carcinoma.
    Hsu CP; Kao TY; Chang WL; Nieh S; Wang HL; Chung YC
    Eur J Surg Oncol; 2011 Feb; 37(2):140-7. PubMed ID: 21194879
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Clinicopathological significance of nuclear pten expression in colorectal adenocarcinoma.
    Jang KS; Song YS; Jang SH; Min KW; Na W; Jang SM; Jun YJ; Lee KH; Choi D; Paik SS
    Histopathology; 2010 Jan; 56(2):229-39. PubMed ID: 20102402
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.
    Siena S; Sartore-Bianchi A; Di Nicolantonio F; Balfour J; Bardelli A
    J Natl Cancer Inst; 2009 Oct; 101(19):1308-24. PubMed ID: 19738166
    [TBL] [Abstract] [Full Text] [Related]  


    of 2.